Press releases

28
Feb

ISO9001 certification

Genoskin obtains ISO9001 certification The entire Genoskin team is proud to announce that we obtained the ISO9001:2015 certification in January 2017. This certificate validates the quality and consistency of our design and R&D services as well as the commercialization of human skin models, cells and tissues to pharmaceutical, chemical and cosmetic industries. Consistent quality for skin models and R&D programs The

Read more

13
Jan

We wish you all the best for the new year

13
Sep

Genoskin launches new website

September 2016. After several months of hard work and dedication, we are thrilled to officially announce the launch of our new website! We invite you to visit us at www.genoskin.com We have built our new website with you in mind. The streamlined user interface provides a more interactive experience, allowing our colleagues, partners, clients and prospects to easily find the information

Read more

30
Jun

Genoskin is a winner of the 7th edition of the NETVA contest: See you soon in Boston !

The NETVA (New Technology Venture Accelerator) program consists in a preparation and exposure to high-tech US markets for young innovative French companies. It is run by the Office for Science & Technology of the Embassy of France in the United States in three locations: Boston, San Francisco and Washington, DC. Each year, 15 French startups are selected though a national competition

Read more

7
May

Australian University uses NativeSkin® models to study UVB skin damage

NativeSkin® successfully treated with UVB after shipment from France to Australia May 2016. Dr. Ziman’s lab. (Edith Cowan University, Perth, Western Australia) reports the successful use of NativeSkin models, shipped from France to Australia, to study skin damages induced by UVB and heat. Researchers analyzed the consequences of UVB and/or heat treatments by co-immunofluorescence staining perform on NativeSkin skin models-fixed tissue, as shown in the

Read more

26
May

Genoskin presents new skin cancer model at Meet2Win

Genoskin launches new OncoSkin® skin cancer model at Meet2Win Genoskin has developed a new skin cancer model for the in vitro study of melanoma. Patients who suffer from this highly dangerous type of skin cancer currently have limited therapeutic options when the cancer reaches metastasis. The OncoSkin® skin cancer model now enables in vitro studies on live melanoma spheroids implanted

Read more